Cytiva: The Company Formerly Known as GE Healthcare Life Sciences and the Gracious Underwriters of This Project

We love to hear from our listeners. Send us a message.

This week's Business Of Biotech pod features Immuneering CEO Dr. Ben Zeskind, who launched his biotech on the back of creative financing in the throes of the Great Recession. A pivot into biopharma landed Immuneering a $20 million series A round to develop its pipeline--at the outset of the COVID-19 pandemic. Dr. Zeskind joins us for a candid and instructive discussion on getting creative when the economy isn't exactly booming. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/